Positive EBITDA, continued growth and high margin
Financial highlights Q4 2023
- Net sales amounted to 22.2 MSEK (18.6), an increase of 19 percent over the same period in 2022.
- Operating result amounted to-3.1 MSEK (-3.6).
- Net result after financial items amounted to-3.7 MSEK (-3.7).
- EBITDA for the Third Quarter is positive at 674 TSEK (-119).
- Earnings per share were-0.05 SEK (-0.06).
- Cash Balance amounted to 7.0 MSEK (6.7).
- Average Daily Treatment Revenue (ADTR)* was 237 TSEK (203), an increase of 17 percent over the same period in 2022
Financial highlights Full Year 2023
- Net sales amounted to 86.1 MSEK (73.0), an increase of 18 percent over 2022.
- Operating Result amounted to-15.0 MSEK (-20.6).
- Net Result after financial items amounted to-17.4 MSEK (-22.4).
- EBITDA for the year is positive at 0.1 MSEK (-6.8).
- Earnings per share were-0.25 SEK (-0.34)
Business highlights during the period
Dignitana announced a sales and marketing partnership withInfuSystem to provide scalp inthe United States .-
Seven states in the southeastern
United States fall under the Local Coverage Determination issued byPalmetto GBA providing coverage for scalp cooling to Medicare recipients as ofNovember 2023 . Dignitana announced theUS Centers for Medicare & Medicaid Services will continue to support scalp cooling however at a reduced average rate beginningJanuary 2024 .Dignitana AB appointed the Nomination Committee for the 2024 Annual General Meeting
Business highlights after the period
Dignitana convenesTraining Academy bringing distributors to Lund Headquarters-
Preliminary results of
DigniCap Delta study inUruguay demonstrate very high efficacy compared to previous studies. Dignitana signs OncoMedical for distribution inSwitzerland andLiechtenstein DigniCap Delta received market approval inJapan withKonica Minolta asDignitana's Distribution partner
Business highlights Full Year 2023
Science International Corporation was announced asDignitana 's distributor inHong Kong andMacao .Dignitana co-sponsored a scalp cooling session at theMultinational Association of Supportive Care in Cancer conference inJapan along with exhibiting at the conference.- A Medicare Local Coverage Determination for Medicare for scalp cooling therapy took effect in seven states in the southeastern US.
- Five year follow up results from the DigniCap pivotal trial were published in the Supportive Care in Cancer journal demonstrating both safety and efficacy in the first long term study of scalp cooling
-
Dignitanas's partnership with oneservice expanded to provide service in the field to DigniCap customers in
Europe . DigniCap Delta was introduced to customers inMexico by Celeritas, DigniCap's longtime partner.
Key Figures
DIGNITANA GROUP | Q4 2023 | Q4 2022 | FY 2023 | FY 2022 |
---|---|---|---|---|
Net sales, TSEK | 21,266 | 20,245 | 86,063 | 72 995 |
Total revenues, TSEK | 21,916 | 21,421 | 89,025 | 83 849 |
Net profit after financial items, TSEK | -4,943 | -11,996 | -17,228 | -22 396 |
Cash and bank balances, TSEK | 6,027 | 8,869 | 6,027 | 8 869 |
Earnings per share before and after dilution, SEK | -0.07 | -0.17 | -0.25 | -0.34 |
verage Daily Treatment revenue, TSEK | 238 | 229 | 239 | 203 |
* ADTR includes pay-per-treatment revenue from patients and facilities in the
"With a strong focus on establishing stable operating expenses to support our scale up strategy, we have grown with high margin while reducing loss." -Catarina Löwenadler, CEO
All financial reports are available at www.dignitana.com/investor-relations/financial-reports/
This disclosure contains information that
For More Information Contact
About
https://news.cision.com/dignitana-ab/r/dignitana-ab-publishes-q4-2023-interim-report,c3929155
https://mb.cision.com/Main/2116/3929155/2606669.pdf
(c) 2024 Cision. All rights reserved., source